Viatris Inc (VTRS)

$10.35 +0.04 (0.39%)
Market Cap 12.02B
Revenue (ttm) 14.74B
Net Income (ttm) -634.20M
EPS (ttm) N/A
PE Ratio 4.32
Forward PE 4.50
Profit Margin -4.30%
Debt to Equity Ratio 1.05
Volume 5,045,600
Avg Vol 8,946,286
Day's Range N/A - N/A
Shares Out 1.17B
Stochastic %K 79%
Beta 0.90
Analysts Sell
Price Target $12.03

Company Profile

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 724 514 1800
Address:
Robert J. Coury Global Center, 1000 Mylan Boulevard, Canonsburg, United States
Whales22
Whales22 Oct. 23 at 7:12 AM
How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $VTRS $EXC $SHLS $COSM Watchlist/
0 · Reply
ShirleyG
ShirleyG Oct. 23 at 12:58 AM
$VTRS $12🤑 let's goooo🚀
0 · Reply
T_L808
T_L808 Oct. 22 at 3:08 PM
$VTRS looks set to reclaim decade (2020's) vwap here
0 · Reply
Winning_calls
Winning_calls Oct. 21 at 3:48 PM
$VTRS 👋👋
0 · Reply
Winning_calls
Winning_calls Oct. 20 at 2:33 AM
$VTRS pick me up @ $10.15
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 10:35 AM
Enter: $VTRS NOV 21 2025 $10 CALLS Buy in Price: $0.50 - $0.60 Take Profit: $1.14 Stop Bleeding: $0.44 ROI Potential: 127% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
ZacksResearch
ZacksResearch Oct. 16 at 3:59 PM
$VTRS expands CNS portfolio with strategic Aculys Pharma acquisition! Gains rights to pitolisant & Spydia in Japan/APAC Positions for growth with late-stage pitolisant seeking approval & approved Spydia Discover how this move could impact Viatris' future 👉 https://www.zacks.com/stock/news/2770348/viatris-acquires-aculys-pharma-to-expand-neurology-portfolio-in-japan?cid=sm-stocktwits-2-2770348-body-16387&ADID=SYND_STOCKTWITS_TWEET_2_2770348_BODY_16387
0 · Reply
ZacksResearch
ZacksResearch Oct. 16 at 2:59 PM
$VTRS expands deeper into Japan’s neurology market The company just acquired Aculys Pharma, adding pitolisant and Spydia to strengthen its CNS lineup for narcolepsy and seizure treatment. See how this deal positions VTRS for long-term growth 👉 https://www.zacks.com/stock/news/2770348/viatris-acquires-aculys-pharma-to-expand-neurology-portfolio-in-japan?cid=sm-stocktwits-2-2770348-teaser-16372&ADID=SYND_STOCKTWITS_TWEET_2_2770348_TEASER_16372
0 · Reply
SniperPro
SniperPro Oct. 15 at 7:50 PM
$BMY $NVO $VTRS $LXRX Surprise, surprise—two editorials mentioning Lexy products! **SAME DAY!!!** I’m sure that’s just a total coincidence, right? Must be some ‘random’ powerful force at play. I wouldn’t be the least bit shocked if the FDA gives the green light to our beloved SOTA future labels... Tick tock! "OCT 15 2025" https://www.morningstar.com/news/accesswire/1087130msn/how-viatris-prevents-and-manages-ncds https://nypost.com/2025/10/14/opinion/operation-warp-speed-ii-can-slash-red-tape-and-save-lives/
0 · Reply
TheG0dFather
TheG0dFather Oct. 15 at 12:35 PM
$VTRS at a minimum $15, deep value right here
0 · Reply
Latest News on VTRS
Teva Vs. Viatris: Who Will Dominate In President Trump's America?

Oct 17, 2025, 12:18 PM EDT - 8 days ago

Teva Vs. Viatris: Who Will Dominate In President Trump's America?

TEVA

Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region

Oct 15, 2025, 4:30 PM EDT - 10 days ago

Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region

Viatris to Participate in Upcoming Investor Conferences

Oct 13, 2025, 6:59 AM EDT - 12 days ago

Viatris to Participate in Upcoming Investor Conferences

Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs

Oct 12, 2025, 10:11 AM EDT - 13 days ago

Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs

AES AMCR ARE BMY CAG CPB DOC

Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row

Oct 8, 2025, 11:00 AM EDT - 17 days ago

Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row

Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 1, 2025, 9:00 AM EDT - 24 days ago

Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025

Viatris: Indore Plant Could Boost 2026 Numbers

Sep 25, 2025, 1:16 PM EDT - 4 weeks ago

Viatris: Indore Plant Could Boost 2026 Numbers

Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

Aug 19, 2025, 9:00 AM EDT - 2 months ago

Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

Dogs Of The S&P 500: Buy 19 Ideal "Safer" August Dividend Payers

Aug 15, 2025, 1:34 PM EDT - 2 months ago

Dogs Of The S&P 500: Buy 19 Ideal "Safer" August Dividend Payers

AMCR ARE BMY BXP CAG CPB CVX

Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.

Aug 11, 2025, 9:29 AM EDT - 2 months ago

Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.

Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 11:02 AM EDT - 2 months ago

Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript

Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise

Aug 7, 2025, 9:36 AM EDT - 2 months ago

Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance

Aug 7, 2025, 6:59 AM EDT - 2 months ago

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance

Viatris Announces Quarterly Dividend

Aug 5, 2025, 6:59 AM EDT - 2 months ago

Viatris Announces Quarterly Dividend

Viatris Announces Appointment of David Simmons to the Company's Board of Directors

Aug 5, 2025, 6:55 AM EDT - 2 months ago

Viatris Announces Appointment of David Simmons to the Company's Board of Directors

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference

Aug 1, 2025, 10:00 AM EDT - 3 months ago

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference

10 dividend stocks with yields up to 6.92% and plenty of cash flow for higher payouts

Jul 22, 2025, 11:19 AM EDT - 3 months ago

10 dividend stocks with yields up to 6.92% and plenty of cash flow for higher payouts

CIVI CMCSA CRGY CWEN KSS LNC NXST

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

Jul 18, 2025, 2:17 PM EDT - 3 months ago

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target

Jul 18, 2025, 8:47 AM EDT - 3 months ago

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target

Viatris eye therapy fails to meet late-stage trial goal

Jul 18, 2025, 7:07 AM EDT - 3 months ago

Viatris eye therapy fails to meet late-stage trial goal

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

Jul 18, 2025, 6:59 AM EDT - 3 months ago

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

Viatris: A Contrarian Bet With Virtually No Downside

Jul 16, 2025, 3:19 AM EDT - 3 months ago

Viatris: A Contrarian Bet With Virtually No Downside

Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys

Jul 11, 2025, 5:23 PM EDT - 3 months ago

Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys

AES AMCR ARE BMY CAG CPB CVX

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

Jun 26, 2025, 6:55 AM EDT - 4 months ago

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 12, 2025, 4:30 PM EDT - 4 months ago

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Jun 9, 2025, 1:06 PM EDT - 4 months ago

Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Viatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference Transcript

Jun 5, 2025, 11:04 AM EDT - 5 months ago

Viatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference Transcript

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

Jun 2, 2025, 1:12 PM EDT - 5 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Jun 2, 2025, 8:00 AM EDT - 5 months ago

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

May 31, 2025, 8:45 AM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

VTRS CLASS NOTICE: Viatris Inc. Investors may have been Affected by Fraud – Contact BFA Law before June 3 Court Deadline (NASDAQ:VTRS)

May 31, 2025, 7:07 AM EDT - 5 months ago

VTRS CLASS NOTICE: Viatris Inc. Investors may have been Affected by Fraud – Contact BFA Law before June 3 Court Deadline (NASDAQ:VTRS)

SHAREHOLDER REMINDER: Berger Montague Reminds Viatris (NASDAQ: VTRS) Investors of the June 3, 2025 Deadline

May 30, 2025, 9:06 AM EDT - 5 months ago

SHAREHOLDER REMINDER: Berger Montague Reminds Viatris (NASDAQ: VTRS) Investors of the June 3, 2025 Deadline

DEADLINE NEXT WEEK: Berger Montague Advises Viatris (NASDAQ: VTRS) Investors to Contact the Firm Before June 3, 2025

May 27, 2025, 10:38 AM EDT - 5 months ago

DEADLINE NEXT WEEK: Berger Montague Advises Viatris (NASDAQ: VTRS) Investors to Contact the Firm Before June 3, 2025

VTRS FRAUD: Suffer Losses on Viatris Inc.? You may have been Affected by Fraud and are Urged to Contact BFA Law (NASDAQ:VTRS)

May 25, 2025, 7:42 AM EDT - 5 months ago

VTRS FRAUD: Suffer Losses on Viatris Inc.? You may have been Affected by Fraud and are Urged to Contact BFA Law (NASDAQ:VTRS)

VTRS FRAUD NEWS: Viatris Inc. is Being Sued for Securities Fraud; Investors That Lost Money Are Urged to Contact BFA Law by June 3 Court Deadline

May 23, 2025, 3:18 PM EDT - 5 months ago

VTRS FRAUD NEWS: Viatris Inc. is Being Sued for Securities Fraud; Investors That Lost Money Are Urged to Contact BFA Law by June 3 Court Deadline

Whales22
Whales22 Oct. 23 at 7:12 AM
How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $VTRS $EXC $SHLS $COSM Watchlist/
0 · Reply
ShirleyG
ShirleyG Oct. 23 at 12:58 AM
$VTRS $12🤑 let's goooo🚀
0 · Reply
T_L808
T_L808 Oct. 22 at 3:08 PM
$VTRS looks set to reclaim decade (2020's) vwap here
0 · Reply
Winning_calls
Winning_calls Oct. 21 at 3:48 PM
$VTRS 👋👋
0 · Reply
Winning_calls
Winning_calls Oct. 20 at 2:33 AM
$VTRS pick me up @ $10.15
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 10:35 AM
Enter: $VTRS NOV 21 2025 $10 CALLS Buy in Price: $0.50 - $0.60 Take Profit: $1.14 Stop Bleeding: $0.44 ROI Potential: 127% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
ZacksResearch
ZacksResearch Oct. 16 at 3:59 PM
$VTRS expands CNS portfolio with strategic Aculys Pharma acquisition! Gains rights to pitolisant & Spydia in Japan/APAC Positions for growth with late-stage pitolisant seeking approval & approved Spydia Discover how this move could impact Viatris' future 👉 https://www.zacks.com/stock/news/2770348/viatris-acquires-aculys-pharma-to-expand-neurology-portfolio-in-japan?cid=sm-stocktwits-2-2770348-body-16387&ADID=SYND_STOCKTWITS_TWEET_2_2770348_BODY_16387
0 · Reply
ZacksResearch
ZacksResearch Oct. 16 at 2:59 PM
$VTRS expands deeper into Japan’s neurology market The company just acquired Aculys Pharma, adding pitolisant and Spydia to strengthen its CNS lineup for narcolepsy and seizure treatment. See how this deal positions VTRS for long-term growth 👉 https://www.zacks.com/stock/news/2770348/viatris-acquires-aculys-pharma-to-expand-neurology-portfolio-in-japan?cid=sm-stocktwits-2-2770348-teaser-16372&ADID=SYND_STOCKTWITS_TWEET_2_2770348_TEASER_16372
0 · Reply
SniperPro
SniperPro Oct. 15 at 7:50 PM
$BMY $NVO $VTRS $LXRX Surprise, surprise—two editorials mentioning Lexy products! **SAME DAY!!!** I’m sure that’s just a total coincidence, right? Must be some ‘random’ powerful force at play. I wouldn’t be the least bit shocked if the FDA gives the green light to our beloved SOTA future labels... Tick tock! "OCT 15 2025" https://www.morningstar.com/news/accesswire/1087130msn/how-viatris-prevents-and-manages-ncds https://nypost.com/2025/10/14/opinion/operation-warp-speed-ii-can-slash-red-tape-and-save-lives/
0 · Reply
TheG0dFather
TheG0dFather Oct. 15 at 12:35 PM
$VTRS at a minimum $15, deep value right here
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 15 at 12:32 PM
$VTRS Share Price: $9.93 Contract Selected: Apr 17, 2026 $10 Calls Buy Zone: $0.77 – $0.95 Target Zone: $1.40 – $1.71 Potential Upside: 73% ROI Time to Expiration: 183 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
JarvisFlow
JarvisFlow Oct. 15 at 11:39 AM
Truist Securities updates rating for Viatris ( $VTRS ) to Buy, target set at 15.
0 · Reply
ItsCarRamRod
ItsCarRamRod Oct. 10 at 5:28 PM
$VTRS well technically it is still trying to hold onto a bullish channel.
2 · Reply
Quantumup
Quantumup Oct. 9 at 10:21 AM
Citizens⬆️the PT on $AQST to $12 from $9, reiterated at a Market Outperform and said that expanded patent protection provides high confidence in Anaphylm's exclusivity through at least 2037 $SPRY $TEVA $VTRS Citizens JMP added, Yesterday, Aquestive announced the issuance of two additional patents for Anaphylm, extending brand exclusivity through at least 2037. We view these patents as meaningfully value accretive as they cover compositions of matter for the novel epinephrine prodrug used in the product candidate. As such, we update our model to project sales through YE2037 (vs. 2034 prior), which drives our increased price target.
0 · Reply
Bamaoracle
Bamaoracle Oct. 6 at 2:04 AM
$VTRS They're being sued by the shareholders over the Indora non disclosure .
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 4 at 1:33 AM
$VTRS Share Price: $10.19 Contract Selected: Apr 17, 2026 $10 Calls Buy Zone: $0.94 – $1.16 Target Zone: $1.76 – $2.15 Potential Upside: 78% ROI Time to Expiration: 195 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 3 at 10:14 PM
Enter: $VTRS NOV 21 2025 $11 CALLS Buy in Price: $0.24 - $0.25 Take Profit: $0.36 Stop Bleeding: $0.21 ROI Potential: 48% Exit Within: 295 Minutes https://moneygroup.us/alerts
0 · Reply
SniperPro
SniperPro Oct. 3 at 2:34 PM
$LXRX $NVO $BMY $VTRS $PFE We’ve got so many positive catalysts ahead! Don’t forget: SOTA USA/EU partner LX9211 partner And who knows what other molecules they’re negotiating behind the scenes—only God knows. The NVO deal came out of nowhere; even I was caught by surprise. At this point, shorting this low is a risky move—anything can happen. MAHA + FDA are not messing around, and this administration knows too many good drugs have been left on the back burner for far too long. 💥 The tide is turning.
1 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 2 at 7:23 PM
🏛️ 🚀 $VTRS up ⬆️6.93% since our entry $9.52 on Sep 26, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!
0 · Reply
ShirleyG
ShirleyG Oct. 2 at 6:03 AM
$VTRS let's goooo!!!! $12🚀📈
0 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 1 at 5:01 PM
🏛️ 🚀 $VTRS up ⬆️6.83% since our entry $9.52 on Sep 26, 2025 👉 FREE TRIAL! Check bio. ALL signals Time stamped. NO B.S.!
0 · Reply
SniperPro
SniperPro Oct. 1 at 4:43 PM
$VTRS $NVO $BMY $LXRX $PFE acquired Arna for $100 per share, and they didn't even have one-third of Lex's assets or the Genome5000 platform—so your calculations are significantly off... Ray knows what he owns... Sota alone, in the right hands and with the right marketing team, has the potential to generate billions of dollars in future revenue. ...
2 · Reply